Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00141063 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

A Phase 3 study of ADHD, sponsored by Novartis.

Completed
Registry status
Phase 3
Development phase
90
Enrollment target
1
Study location

NCT00141063 is a Phase 3 study of ADHD that has completed, run by Novartis. The registered enrollment target is 90 participants, below the 189-participant average among 75 other ADHD trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00141063, a Phase 3 study of ADHD, has completed, sponsored by Novartis.

COMPLETED
Registry status
Phase 3
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the safety and efficacy of two doses of dexmethylphenidate to two doses of an approved, long-acting, marketed medication for ADHD (MPH) and placebo in children ages 6-12 diagnosed with ADHD.

Conditions Studied

Interventions

  • DRUG Focalin XR

Study Locations (1)

Nevada

  • Center for Psychiatry & Behavioral Medicine - Las Vegas

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2005-06
Est. Completion 2005-08
Phase Phase 3

Sponsor

Novartis

265 total trials

What the Registry Record Tells You About NCT00141063

The ClinicalTrials.gov registry entry for NCT00141063 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 75 other ADHD trials with a reported enrollment target (52% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which Focalin XR is the first listed.

NCT00141063 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.

Frequently Asked Questions

What is clinical trial NCT00141063 about?

NCT00141063 is a clinical study titled "Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD". The purpose of this study is to compare the safety and efficacy of two doses of dexmethylphenidate to two doses of an approved, long-acting, marketed medication for ADHD (MPH) and placebo in children ages 6-12 diagnosed with ADHD.

What is the current status of trial NCT00141063?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2005-06. Estimated completion is 2005-08.

What conditions does trial NCT00141063 study?

This clinical trial studies the following conditions: ADHD.

What interventions are being tested in trial NCT00141063?

The interventions under investigation include: Focalin XR (DRUG).

Who is sponsoring clinical trial NCT00141063?

This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00141063 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.